GSK plc (the 'Company')
2025 Performance Share Plan Award
2025 Performance Share Plan Award
On 17 February 2025, the Company granted conditional share awards to the Persons Discharging Managerial Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') listed below under the GlaxoSmithKline 2017 Performance Share Plan ('the Plan'). The Plan was approved by shareholders on 4 May 2017 and allows a performance-related opportunity in the form of conditional awards to be granted to senior executives in the Group, including the Executive Directors and other PDMRs.
Under the terms of the Plan, conditional awards are granted over a specific number of Ordinary Shares or American Depositary Shares ('ADS'), and the percentage of awards that ultimately vests is dependent on the level of achievement against performance targets set by the Remuneration Committee.
The performance period for the awards is the three financial years from 1 January 2025 to 31 December 2027.
The performance measures applicable for the 2025 Plan award will be the subject of a separate release and included in the Company's 2024 Annual Report.
Notes
1. To the extent that each element of a conditional award does not vest at the end of the three-year performance period, it will lapse.
2. The PDMRs in the transaction notifications below were each granted a conditional award under the terms of the GlaxoSmithKline 2017 Performance Share Plan. Awards granted are of Ordinary Shares or ADS.
3. Dividends will accrue on the conditional award of Ordinary Shares or ADS during the performance period but will only vest to the extent that the awards themselves vest at the end of the performance period. These dividends are not included in the figures below.
4. For Executive Directors, the award is subject to an additional vesting period of two years (the 'Holding Period') from the normal vesting date, i.e. five years in total. During the additional Holding Period, the relevant Ordinary Shares or ADS would only be forfeited in the event that the Executive Director was terminated for cause, and the Ordinary Shares or ADS will continue to carry rights to dividend equivalents.
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Emma Walmsley | |||
| b) | Position/status | Chief Executive Officer | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £14.35 | 573,313 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
|
Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-02-17 | |||
| f) | Place of the transaction
| N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Julie Brown | |||
| b) | Position/status | Chief Financial Officer | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £14.35 | 285,072 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
|
Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-02-17 | |||
| f) | Place of the transaction
| N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Diana Conrad | |||
| b) | Position/status | Chief People Officer | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £14.35 | 112,442 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
|
Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-02-17 | |||
| f) | Place of the transaction
| N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | James Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £14.35 | 194,320 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
|
Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-02-17 | |||
| f) | Place of the transaction
| N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Sally Jackson | |||
| b) | Position/status | SVP, Global Communications and CEO Office | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan
| |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £14.35 | 81,690 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
|
Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-02-17 | |||
| f) | Place of the transaction
| N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Luke Miels | |||
| b) | Position/status | Chief Commercial Officer | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan
| |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £14.35 | 298,713 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
|
Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-02-17 | |||
| f) | Place of the transaction
| N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Shobie Ramakrishnan | |||
| b) | Position/status | Chief Digital and Technology Officer | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADS')
ISIN: US37733W2044 | |||
| b) | Nature of the transaction | A conditional award of ADS under the Company's 2017 Performance Share Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $36.17 | 69,302 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
|
Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-02-17 | |||
| f) | Place of the transaction
| N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | David Redfern | |||
| b) | Position/status | President, Corporate Development | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan
| |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £14.35 | 208,247 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
|
Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-02-17 | |||
| f) | Place of the transaction
| N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Regis Simard | |||
| b) | Position/status | President, Global Supply Chain | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan
| |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £14.35 | 218,217 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
|
Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-02-17 | |||
| f) | Place of the transaction
| N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Philip Thomson | |||
| b) | Position/status | President, Global Affairs | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan
| |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £14.35 | 96,047 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
|
Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-02-17 | |||
| f) | Place of the transaction
| N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Deborah Waterhouse | |||
| b) | Position/status | CEO, ViiV Healthcare and President, GSK Global Health | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan
| |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £14.35 | 198,094 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
|
Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-02-17 | |||
| f) | Place of the transaction
| N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Anthony Wood (Tony) | |||
| b) | Position/status | Chief Scientific Officer | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £14.35 | 276,842 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
|
Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-02-17 | |||
| f) | Place of the transaction
| N/A | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Victoria Whyte | |||
| b) | Position/status | Company Secretary | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan
| |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £14.195 | 11,800 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
|
Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-02-17 | |||
| f) | Place of the transaction
| N/A | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.